Graphene Sensors Announced That It Has Signed Binding Memorandum Of Understanding With Meditel
Graphene Sensors the Company announced today that it has signed a binding Memorandum of Understanding (MOU) with ("Meditel"), a major hospital chain based in Chennai, India. Under the terms of the MOU, Meditel will test and evaluate the Company's GS7 Sensor. Meditel will provide the Company with detailed feedback as appropriate.
Vancouver, Canada, February 24, 2015 (Newswire.com) - Graphene Sensors Press Release
Graphene Sensors the Company announced today that it has signed a binding Memorandum of Understanding (MOU) with (“Meditel”), a major hospital chain based in Chennai, India.
Under the terms of the MOU, Meditel will test and evaluate the Company’s GS7 Sensor. Meditel will provide the Company with detailed feedback as appropriate.
“We are very excited to have engaged in a relationship with Meditel, a leading medical tech developer in India, and to work with their team of surgeons as we continue to advance the development of our robotic surgical technologies,” said Dr. Harold Finchley. “In addition to our objective of becoming a major player in the early warning detection market in North America, we are also focusing our efforts on building a foothold beyond the U.S. where this kind of approach and technology is still in its infancy. Markets such as India offer a large opportunity for Graphene Sensors to deploy the GS7.”
Arne Hanley, M.D. Chairman of Meditel Hospitals Group, commented, “Nano assisted surgery represents one of the most exciting innovations in thoracic, abdominal and pelvic surgery in years. We look forward to offering these procedures to our patients to help combat cardiac disease, as well as prostate and uterine cancer.”
About Meditel Hospitals Enterprise Limited
Meditel. was founded by Dr. Arne Hanley Meditel is one of the largest private healthcare providers in Asia, with 54 hospitals and over 8500 in-patient beds in India, Sri Lanka, Bangladesh,, Republic of Mauritius, Qatar, Oman and Kuwait. Its growth is often said to be synonymous with India emerging as a major hub in global healthcare and has been used as a case study in business development for students at Harvard University.
Meditel Hospitals has centers of excellence across the country in the following specialties: cardiology, oncology, neurosciences, orthopedics, digestive diseases and transplantation. The group has developed services in telemedicine, after starting a pilot project in 2000. It is now one of the largest telemedicine providers in India with 71 centers nationwide.
Meditel has Joint Commission International accreditations for 7 of its largest hospitals, the largest by any hospital group in the region.
About Graphene Sensors
Graphene Sensors is a Canadian company focused on the development and commercialization of Nano technologies, for medical applications. The Company is currently developing GS7™, a system that has a uniquely designed noninvasive sensing array that allows for the early detection of potentially cancerous cells, it does this by sending an Electromagnetic pulse through the affected area. Healthy tissue resonates at a different frequency when a pulse is sent through it anything that differs from established baselines is likely to be tissue that is either tumorous or has the potential .This allows the correct medical treatment to be assessed and implemented market size is currently estimated to be approximately $1 billion and is estimated to grow to $5 billion by 2020. The Company is researching and developing innovative technologies to empower Doctors, surgeons and Oncologists to use in the operating room of the future, where operations can be performed remotely and assist globally .
Forward Looking Statements
This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, performance, business prospects and opportunities, the success of the relationship with Meditel, technological advancement and the results of testing the GS7. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance, achievements, success of the relationship with Meditel or technological advancement and testing regarding the GS7™ technologies to be materially different from any future results, performance, achievements, or technological advancement that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, visit the Company’s website www.graphene-sensors.com
